Maximize Your Molecule’s Full Potential

Click here to view our new

INTERACTIVE BROCHURE

VISIT US

Stand 121F81,

ICSE General floor

Formulation challenges. Clinical supply hurdles. Limited manufacturing capability or capacity. Market fluctuations and demand surges. Lifecycle management. Risk mitigation. Patent expiry concerns. 

At BioPharma Solutions, a business unit of Baxter, we know the high-stakes challenges you face in today’s complex parenteral marketplace — and how the work we do is vital to the patients you serve.

That’s why we work closely with you at every step to help you achieve your molecule’s full potential and your commercialization objectives — building on over 85 years of Baxter innovation, expertise, and specialization in parenterals. 

To discuss sterile contract manufacturing services for injectable molecules, please contact us at:  
United States: 1-800-4-BAXTER 
International: 1-2 24-948-4770

Go to article: Home | Advancing adherenceGo to article: Scandinavian Health Company InsightGo to article: Scandinavian Health Ltd.Go to article: EditorialGo to article: PfanstiehlGo to article: Pfanstiehl Company InsightGo to article: ContentsGo to article: Daiichi JitsugyoGo to article: Owen MumfordGo to article: NewsGo to article: TSS Company InsightGo to article: TSS ABGo to article: Novo NordiskGo to article: The pharma industry briefingGo to article: AtoZ-CRO Company InsightGo to article: AtoZ-CRO GmbHGo to article: Timeline: using viruses to fight diseaseGo to article: Swiss WorldCargoGo to article: AirBridgeCargo Company InsightGo to article: AirBridgeCargoGo to article: Q&A: an eye on innovation with SparingVisionGo to article: MasterpackGo to article: Molnar Company InsightGo to article: MolnarGo to article: B&W TekGo to article: Could smart pill bottles dispense a solution to drug non-adherence?Go to article: Hapa Company InsightGo to article: Qatar AirwaysGo to article: Dow EuropeGo to article: WHO’s Essential Medicines List: discussing innovation and accessGo to article: Erdmann Design SwitzerlandGo to article: AEB Company Insight Go to article: AEBGo to article: Centaur Clinical | Company InsightGo to article: Centaur ClinicalGo to article: Are we nearing the end of animal testing in pharma?Go to article: ImmuMap Company Insight Go to article: ImmuMapGo to article: Barc Lab Go to article: Why is pharma so bad at sharing clinical trial data?Go to article: SmartCAE Company InsightGo to article: SmartCAEGo to article: Capsugel Company InsightGo to article: Unseen genes: boosting African DNA in medical researchGo to article: Emirates SkyCargoGo to article: Pfeiffer VacuumGo to article: Could Netflix-style subscription models work for medicines?Go to article: HOF Sonderanlagenbau Company InsightGo to article: HOF SonderanlagenbauGo to article: MicronovaGo to article: AlpexGo to article: EventsGo to article: Senn Chemicals Company InsightGo to article: Senn ChemicalsGo to article: ICCI Company InsightGo to article: ICCIGo to article: Next issueGo to article: CBDepot Company InsightGo to article: CBDepotGo to article: Nemera Company InsightGo to article: NemeraGo to article: Komtur Pharmaceuticals Company InsightGo to article: Komtur PharmaceuticalsGo to article: MimotopesGo to article: Baxter